SavedAdd your journal

Journals / Türk Kardiyoloji Derneği Arşivi / 2010 / Cilt: 38 - Sayı: 4

İki farklı aspirin dozu ile platelet fonksiyon analizi

Platelet function analysis with two different doses of aspirin

Cihan ALTIN
Aylin YILDIRIR
Aslı ATAR
İlyas ATAR
Alp AYDINALP
Sadık AÇIKEL
Haldun MÜDERRİSOĞLU
Hüseyin BOZBAŞ
Öykü GÜLMEZ
Pages
239–243
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Incomplete platelet inhibition was defined as a normal collagen/epinephrine closure time (

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: We aimed to compare the level of platelet inhibition using the platelet function analyzer (PFA)-100 in patients receiving low and medium doses of aspirin.Study design: On a prospective basis, 159 cardiology outpatients (83 men, 76 women; mean age 60.9±9.9 years) taking 100 mg/day or 300 mg/day aspirin at least for the previous 15 days were included.
📊
Key Findings & Data:Of these, 79 patients (50%) were on 100 mg and 80 patients (50.3%) were on 300 mg aspirin treatment.
💡
Conclusion & Impact:Incomplete platelet inhibition was defined as a normal collagen/epinephrine closure time (
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: We aimed to compare the level of platelet inhibition using the platelet function analyzer (PFA)-100 in patients receiving low and medium doses of aspirin.Study design: On a prospective basis, 159 cardiology outpatients (83 men, 76 women; mean age 60.9±9.9 years) taking 100 mg/day or 300 mg/day aspirin at least for the previous 15 days were included. Of these, 79 patients (50%) were on 100 mg and 80 patients (50.3%) were on 300 mg aspirin treatment. Blood samples were collected between 09:30 and 11:00 hours in the morning. Platelet reactivity was measured with the PFA-100 system. Incomplete platelet inhibition was defined as a normal collagen/epinephrine closure time (

Özet

Amaç: Düşük ve orta dozda aspirin kullanan hastalarda platelet fonksiyon analizi (PFA-100) ile platelet inhibisyon derecelerin kıyaslanması planlandı.Çalışma planı: En az son 15 gündür 100 mgr/gün veya 300 mgr/gün aspirin kullanan 159 poliklinik hastası (83 erkek, 76 kadın; ort. yaş 60.9±9.9) ileriye dönük olarak çalışmaya alındı. Bu hastaların 79’u (%50) 100 mgr, 80’i (%50.3) ise 300 mgr dozda aspirin almaktaydı. Hastalardan kan örnekleri sabah 09:30-11.00 saatleri arasında alındı. Platelet reaktivitesi PFA-100 sistemiyle ölçüldü. Yetersiz platelet inhibisyonu, aspirin tedavisine rağmen PFA-100 sisteminde kolajen/epinefrin kapanma zamanının normal bulunması (

🔖

Cite This Article

ALTIN, C., YILDIRIR, A., ATAR, A., ATAR, İ., AYDINALP, A., AÇIKEL, S., MÜDERRİSOĞLU, H., BOZBAŞ, H., GÜLMEZ, Ö. (2022). İki farklı aspirin dozu ile platelet fonksiyon analizi. Türk Kardiyoloji Derneği Arşivi, Cilt: 38 - Sayı: 4, 239–243. https://ajindex.com/articles/633266

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Steering Committee of the Physicians’ Health Study Research Group. Final report on the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med 1989;321:129-35
  2. Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106
  3. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86
  4. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502
  5. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:349-60
  6. Patrono C. Aspirin and human platelets: from clinical trials to acetylation of cyclooxygenase and back. Trends Pharmacol Sci 1989;10:453-8
  7. Gurbel PA, Bliden KP, DiChiara J, Newcomer J, Weng W, Neerchal NK, et al. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation 2007;115:3156-64
  8. DiChiara J, Bliden KP, Tantry US, Hamed MS, Antonino MJ, Suarez TA, et al. The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study. Diabetes 2007;56:3014-9
  9. Hovens MM, Snoep JD, Eikenboom JC, van der Bom JG, Mertens BJ, Huisman MV. Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. Am Heart J 2007;153:175-81
  10. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 2008; 336:195-8
  11. Akay OM, Cantürk Z, Akın E, Bal C, Gülbas Z. Aspirin-resistance frequency: a prospective study in 280 healthy Turkish volunteers. Clin Appl Thromb Hemost 2009;15:98-102
  12. Lee PY, Chen WH, Ng W, Cheng X, Kwok JY, Tse HF, et al. Low-dose aspirin increases aspirin resistance in patients with coronary artery disease. Am J Med 2005;118:723-7
  13. Gum PA, Kot